The market battle between Roche’s Vabysmo and Regeneron and Bayer’s Eylea just cranked up a notch. With Vabysmo’s FDA approval to treat retinal vein occlusion (RVO), the rival eye meds share another ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...
Please provide your email address to receive an email when new articles are posted on . “We achieved our main goals for the study,” Frostegård said. “We see that ANXV is well tolerated and safe, and ...
Please provide your email address to receive an email when new articles are posted on . The 13 patients who completed the trial were given five intravenous treatments of ANXV (Annexin Pharmaceuticals) ...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...
Sept. 16 -- TUESDAY, Sept. 15 (HealthDay News) -- Researchers report they've found the first long-term treatment for people who suffer vision loss when the large veins in their eyes become blocked.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback